A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa
The ICERs of long acting insulins were considerably higher than South Africa's indicative cost-effectiveness threshold. The status quo of NPH insulin in the management of T1DM in adults remains the most cost-effective option for the South African public health sector.
Authors
- Susan Cleary (ORCID: https://orcid.org/0000-0002-9071-7958)
- Mark T. Verryn
Institutions
- University of Cape Town (ZA)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1186/s12962-025-00615-x
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00